Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed during childhood. Although the 5-year survival rate of children treated for ALL is now above 80%, a considerable proportion of these children continue to relapse or die during or after completing therapy. The anti-folate cancer drug, methotrexate (MTX), is a critical component of ALL chemotherapy protocols and poor cellular response to MTX can substantially contribute to treatment failure in children treated for ALL. 1 Moreover, recent studies have also provided evidence suggesting that common polymorphisms in genes of the folate pathway may play an important role in determining treatment efficacy and toxicity in patients treated for ALL. [2] [3] [4] Two common polymorphisms have been extensively described in the MTHFR gene. The first polymorphism, MTHFR C677T, involves a C to T transition causing an alanine to valine substitution at amino acid position 222, whereas the second, MTHFR A1298C, involves an A to C transversion causing a glutamic acid to alanine replacement at amino acid position 429. Both of these variants have been shown to have an impact on enzyme activity. Earlier studies have shown enzymatic activity to be reduced by up to 60% in individuals homozygous for MTHFR 677TT and to a lesser extent in those heterozygous for MTHFR 677TC, whereas other studies have shown that the MTHFR 1298C polymorphism results in decreased enzyme activity in vitro, although not to the levels observed in carriers of the MTHFR 677T polymorphism (reviewed by Schwahn and Rozen 5 ). Investigators have also reported an increased frequency of MTHFR 677TT homozygosity in leukaemia patients intolerant to MTX, suggesting that the MTHFR 677TT polymorphism is associated with increased MTX toxicity or reduced survival, owing to interference with MTX activity. 3, 5 Investigators have also reported a functional polymorphism in the reduced folate carrier gene (RFC G80A) that causes an arginine to histidine substitution at amino acid position 27 and affects folate and homocysteine levels in healthy individuals. 6, 7 Although the RFC 80A allele variant has been shown to improve Letters to the Editor MTX-treatment efficacy in patients with rheumatoid arthritis, few studies have investigated the clinical implications of this polymorphism in children with ALL and these have produced variable results. One study examining 205 children with ALL treated with MTX induction and maintenance therapy reported that patients homozygous or heterozygous for the RFC 80A allele had a significantly shorter event-free survival (EFS) compared with those homozygous for RFC 80G.
2 However, a more recent study examining 246 paediatric patients treated with high-dose MTX therapy found no increased risk of hematological relapse by RFC G80A genotype. 4 We examined the frequencies of the RFC G80A and MTHFR C677T gene polymorphisms occurring in a cohort of 170 children with ALL treated on the same therapeutic protocol and investigated their association with the risk of relapse or death in the 5 years after diagnosis. Analysis of MTHFR C677T and MTHFR A1298C genotype combinations (haplotypes) were also examined in a subset of 148 patients for whom DNA was available. For diagnosis, bone marrow samples were obtained after receiving informed consent from pediatric ALL patients enrolled in the Australia and New Zealand Children's Cancer Study Group ALL Study VI Protocol. All children with ALL diagnosed between April 1992 and December 1997 were uniformly treated on the Study VI chemotherapy protocol and followed up to January 2002. Of the 597 children enrolled in the Australia and New Zealand Children's Cancer Study Group Study VI Trial, 170 children with stored DNA samples were included in our study. The distribution of age, sex, immunophenotype, white cell count (WCC) at diagnosis and cumulative EFS did not differ significantly between the 170 patients included in our study and the 597 children enrolled in the Study VI trial (P40.05, see Supplementary information and Supplementary Table 1 ). Clinical data, including age, sex, ALL subtype and WCC at diagnosis and dates of diagnosis, relapse and death were obtained from medical records. Genomic DNA was isolated from diagnosis samples using conventional techniques.
Quantitative real-time PCR assays were performed in an ABI Prism 7000 sequence detection system using the TaqMan PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to manufacturer's instructions. To confirm the results of the real-time PCR RFC genotyping, a subset of 100 DNA samples was examined by conventional PCR amplification (see Supplementary Table 2 ). Concordance of RFC and MTHFR genotype frequencies with Hardy-Weinberg equilibrium was tested by w 2 -test. The cumulative EFS was computed by the method of Kaplan-Meier and compared between subgroups using logrank tests. Children were considered to have an event if relapse or death attributable to disease occurred within 5 years of diagnosis. The influence of MTHFR and RFC gene variants, as well as established prognostic factors (sex, age and median WCC at diagnosis, ALL subtype) on EFS time was analyzed using a Cox proportional hazards model. All statistical calculations were carried out using Stata, version 10.0, 2007 (StataCorp, College Station, TX, USA).
All MTHFR C677T genotypes were found to be in HardyWeinberg equilibrium (Table 1 ) and allele frequencies, MTHFR C allele of 65.15% and MTHFR T allele of 34.85%, were consistent with earlier reports. 3 The MTHFR C677T genotype could not be determined for five of 170 patients analyzed. The cumulative 5 year EFS was 57% in those homozygous for MTHFR 677CC (95% CI ¼ 73-90%); 62% in those heterozygous for MTHFR 677CT (95% CI ¼ 48-74%); and 55% in those homozygous for MTHFR 677TT (95% CI ¼ 31-74%). No significant difference in EFS was observed between individual MTHFR genotypes (logrank test, P ¼ 0.370), or when combined MTHFR C677T genotypes were considered (logrank test, P ¼ 0.230; Figure 1 ). Multivariate analysis showed that MTHFR genotype was not significantly associated with EFS after adjusting for median WCC at diagnosis, age, sex and RFC Table 1 Associations between RFC and MTHFR genotypes and EFS in children with ALL Table 1 ). Combined analysis of MTHFR C677T and MTHFR A1298C genotypes in a subset of 148 patients showed that the risk of an event in carriers of the MTHFR T677A1298 or the MTHFR C677C1298 haplotype did not differ from non-carriers of these haplotypes (see Supplementary Table 3) . RFC genotypes were determined for all 170 patients analyzed and were in Hardy-Weinberg equilibrium (Table 1) . Allele frequencies were found to be 60% for the RFC G allele variant and 40% for the RFC A allele variant and were similar to those reported elsewhere. 8 The cumulative 5 year EFS was 47% in those homozygous for RFC 80GG (95% CI ¼ 31-61%); 64% in those heterozygous for RFC 80GA (95% CI ¼ 52-74%) and 73% in those homozygous for RFC 80AA (95% CI ¼ 45-88%). Kaplan-Meier survival analysis showed that EFS was significantly lower for individuals with RFC 80GG by comparison with the other RFC genotypes individually (logrank test, P ¼ 0.024), or when RFC 80GA and RFC 80AA genotypes were combined (logrank test, P ¼ 0.007; Figure 2 ). Univariate analysis showed that patients who were heterozygous or homozygous for the RFC 80A allele were at least 50% more likely to remain event free during follow-up compared with those who were homozygous for RFC 80G (Table 1) . This association was also observed when combined heterozygous (RFC 80AG) and homozygous (RFC 80AA) RFC genotypes were considered (HR ¼ 0.50, 95% CI ¼ 0.30-0.84, P ¼ 0.009) and remained significant in multivariate analysis after adjusting for median WCC at diagnosis and sex (HR ¼ 0.528; 95% CI ¼ 0.31-0.89; P ¼ 0.017). The risk of an event in individuals carrying at least one copy of the MTHFR T677 and RFC 80A variant alleles compared with noncarriers was not significant at a probability level of 0.05 (HR ¼ 0.73, 95% CI ¼ 0.41-1.29, P ¼ 0.278; Table 1 ).
As genes of the folate pathway are key players in MTX uptake and metabolism, the presence or absence of specific allelic variants in these genes is likely to modulate the therapeutic response to MTX treatment in children with ALL. We found children with ALL who were carriers of the RFC 80A allelic variant were 50% less likely to relapse or die during follow-up compared with individuals without the RFC 80A allelic variant. However, no association between MTHFR C677T genotype and cumulative EFS was observed in our study population. Downregulation of RFC gene expression, modification of protein structure and decreased MTX affinity for the RFC protein have been linked to increased MTX resistance and decreased MTX uptake into cells. 1, 2, 6 Although we have shown earlier that transfection of the 80GG and 80AA RFCs into transport-deficient K562 cells did not yield substantial functional differences between these two proteins, 7 subtle variations in these RFC forms may still be clinically important as a relatively small increase of MTX resistance in cells obtained at relapse compared with cells obtained at diagnosis may render patients clinically resistant to chemotherapeutic drugs. Higher cellular accumulation of MTX polyglutamates has been observed in ALL cells overexpressing RFC. 1 Moreover, the RFC 80AA genotype has been reported to be associated with higher plasma folate in healthy controls compared with RFC 80GG 6 and two-fold higher levels of long-chain MTX polyglutamates have been observed in red blood cells obtained from rheumatoid arthritis patients with the RFC 80AA genotype compared with patients with either RFC 80GG or RFC 80GA genotypes. 9 Although studies examining the RFC G80A genotype in groups of children with ALL are limited, investigations in patients with rheumatoid arthritis have shown that individuals with the RFC 80AA genotype are more likely to have a superior Letters to the Editor clinical response to MTX therapy. 9 Our finding of a positive association between the RFC 80A variant allele and improved survival is in contrast to that of a French-Canadian study that showed a negative association between the RFC 80A variant allele and EFS in children with ALL. 2 The reason for this observed difference is unclear although there are a number of possible explanations. ALL patients in our study were uniformly treated in a single clinical trial, whereas those in the FrenchCanadian study were treated on three different chemotherapy regimes. 2 Earlier investigations have indicated that the effect of the RFC G80A polymorphism may be more evident in patients given low-dose MTX. 1 Hence, the observed differences in the association between RFC G80A genotype and survival in ours and the French-Canadian study may, in fact, be a function of subtle differences in the individual chemotherapy regimes. Alternatively, variable clinical associations with the RFC G80A genotype may have been because of the ethnic composition of the two populations examined or effect modification by other gene polymorphisms not examined in either study.
Although the RFC 80A allele frequency may vary between different ethnic groups, both the MTHFR and RFC allele frequencies observed in our study were consistent with those reported earlier in other Caucasian populations. Although we observed a slightly lower frequency of individuals homozygous for RFC 80AA (13.5%) than the earlier studies, this finding was similar to that observed in a recent study of 460 childhood ALL patients for which the RFC 80AA frequency was 17.4%. 8 The observed frequencies in our study are unlikely to be because of genotyping error from real-time PCR allelic discrimination as we obtained the same genotyping results for 100 samples re-tested using conventional PCR analysis.
Despite limited evidence showing a positive association between the MTHFR C677T polymorphism and EFS in children with ALL or patients treated for rheumatoid arthritis, 3, 5 such an association was not apparent in our study. To some extent, our null finding may have been because of the limited number of gene variants that we examined in the folate metabolic pathway. Several studies have suggested that the intracellular effect of MTX may be influenced by other enzymes in the folate metabolic pathway and that variations in the genes encoding these enzymes may modify the therapeutic response to MTX. 3, 4 For example, children with ALL with the MTHFR 677T/1298A haplotype and the 3R3R genotype of the TS gene have been shown to have a substantially lower probability of a 5 year EFS compared with those with the MTHFR 677T/1298A haplotype, but not the TS 3R3R genotype. 3 Overall, our findings suggest that the RFC G80A polymorphism may influence outcome in childhood ALL patients being treated with MTX. However, it will be important in future studies to consider a range of gene polymorphisms in the folate metabolic pathway, known to alter enzyme function, alone and in combination, in a much larger cohort of patients, in order to identify combinations of genotypes that may influence the clinical response to MTX treatment. The clinical importance of these polymorphisms is also likely to be dependent on anti-cancer treatment regimens in the presence or absence of leucovorin rescue therapy, as well as the folate intake of patients. Such information may ultimately allow for individualisation of chemotherapy regimens for specific patients.
